The Journey of Metformin

Metformin is a hydrophilic biguanide with near-zero lipophilicity
(logP = -6.1), meaning passive diffusion across intestinal membranes is negligible. It relies
almost entirely on active transport systems. The primary carrier in the small intestine is plasma
membrane monoamine transporter (PMAT, SLC29A4) and organic cation transporter 3 (OCT3, SLC22A3),
with contributions from organic cation transporter 1 (OCT1, SLC22A1). Bioavailability is
50-60% at standard doses. Peak plasma concentrations occur 2-3 hours after immediate-release
tablets. Extended-release formulations achieve lower peak concentrations with similar overall
exposure. Absorption is slightly reduced by food but clinical effect is similar. The drug is
not absorbed in the colon, which is why extended-release formulations that rely on colonic
delivery have variable efficacy depending on GI transit time.

Once in portal blood, metformin is actively transported into
hepatocytes by OCT1 and OCT3. Hepatic concentrations are estimated to be 50-100-fold higher
than plasma — a crucial pharmacokinetic feature because the liver is the primary organ for
metformin's glucose-lowering action. Unlike most drugs, metformin does not bind to plasma
proteins. Its volume of distribution is large (63-276 L), reflecting accumulation in tissues
including gut wall, liver, kidney, and skeletal muscle. Red blood cell concentrations approximate
whole blood concentrations. The drug does not cross the blood-brain barrier appreciably. Its
preferential accumulation in gut enterocytes has led to the hypothesis that a significant part
of its glucose-lowering effect originates in the intestinal lumen — increasing GLP-1 secretion,
altering bile acid cycling, and modifying the gut microbiome composition.

Metformin's mechanism of action remained elusive for 60 years
after its clinical introduction. The current consensus centers on two interrelated effects.
First, metformin inhibits mitochondrial complex I (NADH:ubiquinone oxidoreductase) in hepatocytes,
mildly but sufficiently to reduce the mitochondrial membrane potential and lower the ATP/ADP and
ATP/AMP ratios. The resulting rise in cellular AMP activates AMP-activated protein kinase (AMPK),
a master energy sensor. Active AMPK phosphorylates and inactivates acetyl-CoA carboxylase,
activates malonyl-CoA decarboxylase, and suppresses transcription of gluconeogenic genes
(PEPCK, G6Pase) through phosphorylation of CRTC2 and inhibition of the CBP-TORC2 complex.
Second, metformin may have AMPK-independent effects: inhibition of mitochondrial glycerophosphate
dehydrogenase reduces cytosolic redox potential, limiting the availability of lactate and glycerol
as gluconeogenic substrates. The net result is a 25-35% reduction in hepatic glucose output.
Metformin also modestly increases peripheral insulin sensitivity in muscle.

Metformin is not metabolized by the liver or any other organ.
It circulates unchanged and is eliminated exclusively by the kidney. No cytochrome P450 enzymes
are involved. This absence of hepatic metabolism is clinically important: metformin lacks drug-drug
interactions arising from CYP enzyme induction or inhibition, and hepatic impairment does not
alter its pharmacokinetics (though it is contraindicated in severe liver disease due to lactate
acidosis risk from impaired lactate clearance). The drug does not form active or toxic metabolites.

Metformin is eliminated entirely unchanged by the kidneys via active
tubular secretion mediated by multidrug and toxin extrusion proteins MATE1 (SLC47A1) and MATE2-K
(SLC47A2) on the apical tubular membrane, combined with OCT2-mediated basolateral uptake. Renal
clearance (500 mL/min) greatly exceeds glomerular filtration rate (125 mL/min), confirming
dominant tubular secretion. Half-life is 4-9 hours. In renal impairment, metformin accumulates and
increases the risk of lactic acidosis — the primary safety concern that leads to dose reduction
when eGFR drops below 45 mL/min/1.73m² and contraindication below 30 mL/min/1.73m².

Metformin remains the first-line pharmacotherapy for type 2 diabetes
due to its efficacy (HbA1c reduction 1-2%), weight neutrality or mild weight loss, cardiovascular
benefit (UKPDS), and low cost. It does not cause hypoglycemia when used as monotherapy. OCT1
genetic polymorphisms influence response — carriers of loss-of-function variants (especially
SLC22A1 rs622342) show attenuated HbA1c reduction. Co-administration of cationic drugs competing
for MATE transporters (cimetidine, trimethoprim, vandetanib) can increase metformin plasma levels
by 50-60%. Iodinated contrast agents may transiently reduce renal clearance, requiring temporary
suspension in at-risk patients.